Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPY4R | P50391 | 3/20 | 0.30 |
| ▸ | NPY1R | P25929 | 2/20 | 0.30 |
| ▸ | NPY2R | P49146 | 2/20 | 0.30 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11950333 | 0.89 | NPY4R (0.38) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL8227032 | 0.89 | NPY4R (0.38) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL14028975 | 0.89 | NPY4R (0.38) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL19487472 | 0.88 | ALOX15 (0.39) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL18356744 | 0.88 | ALOX15 (0.39) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL30208240 | 0.85 | TGFBR1 (0.32) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL19487357 | 0.85 | KISS1R (0.31) | — | |
| SCHEMBL26466762 | 0.82 | ANPEP (0.30) | ALOX15 | |
| SCHEMBL26546113 | 0.82 | ALOX15 (0.30) | ALOX15 | |
| SCHEMBL14942945 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190345202-A1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345202-A1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | AR, NR5A1, NR5A2 | ALOX15 760/4885MEN1 3408/4885CYP1A2 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.